Becoming the Leader in Treating Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System
Learn more Career Opportunities
Corbus Pharmaceuticals is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates.
Learn MoreOur technology is built on robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.
Learn MoreCorbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with chronic inflammatory and fibrotic conditions.
Learn MoreOur pipeline is built on robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.
View DetailsPreclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Launch Phase not started
|
Targeting 2021 launch
Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Launch Phase not started
|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Launch Phase not started
|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Launch Phase not started
|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
---|---|---|---|---|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Launch Phase not started
|
Scheduled to Enter Phase 1 in 2019, NIH Committed to Funding Phase 2 Study.
Goal: 1-2 new Phase 1 programs per year starting in 2020
Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
---|---|---|---|---|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Launch Phase not started
|
A novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes.